Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

NUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

NUEDEXTA Important Safety Information

NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindica
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 ViiV Healthcare, Aurobindo ... announced today that Aurobindo Pharma has submitted an Abbreviated ... Approval, to the Food and Drug Administration (FDA), for ... for a generic version of dolutegravir, less than two ... in the United States . ...
(Date:5/26/2015)...  Respiratory Motion, Inc. – Research being presented ... the Japanese Society of Anesthesiologists shows that commonly ... miss critical early indicators of impending deterioration and ... that respiratory volume monitoring using the ExSpiron™ Patient ... patients than traditional capnography and pulse oximetry technologies ...
(Date:5/26/2015)... 2015 Helping seniors stay as independent ... be a full-time job for families and caregivers. ... gap when they can,t be with their aging ... eHeart Health Monitoring, LLC , not all personal ... Photo - ...
Breaking Medicine Technology:ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 2ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 3ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 4ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 5ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 6ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 7Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression 2Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression 3Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression 4Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression 5eHeart Health Monitoring Gives Tips on Choosing the Right Personal Alert System for Aging Loved Ones 2eHeart Health Monitoring Gives Tips on Choosing the Right Personal Alert System for Aging Loved Ones 3eHeart Health Monitoring Gives Tips on Choosing the Right Personal Alert System for Aging Loved Ones 4
... 4, 2010 Poniard Pharmaceuticals, Inc. (Nasdaq: ... therapies, today announced that it has been awarded $244,479 ... Qualifying Therapeutic Discovery Project (QTDP) program established under Section ... use the grant to advance the development of its ...
... Nov. 4, 2010 Eli Lilly and Company (NYSE: ... Officer John Lechleiter Ph.D. today presented an $11.6 million ... contributions of Lilly,s U.S. employees and retirees and a ... were raised for the Central Indiana chapter and other ...
Cached Medicine Technology:Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program 2Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program 3Lilly Surpasses United Way 2010 Campaign Goal 2
(Date:5/26/2015)... 26, 2015 On June 4, 2015, ... live online broadcast at 6:00pm PST/9:00 pm EST. ... Master™ Alice Branton welcomes the public to attend and ... of profound knowledge, transformation and enlightenment. The webinar ... no previous knowledge, experience or other prerequisites are required. ...
(Date:5/26/2015)... Writers and editors can use the ... to make creating, editing, and managing content a ... management system (CCMS) software provider, certified that their ... Editor Version 17.0, Syncro Soft’s latest software update. ... key editorial functionality of the Vasont CCMS into ...
(Date:5/26/2015)... Glendale, CA (PRWEB) May 26, 2015 ... joined forces with MarkLogic Corporation. The alliance ensures ... NoSQL database platform and General Networks’ expertise in ... General Networks and MarkLogic will help customers integrate, ... improve decision-making and business processes. , “Our customers ...
(Date:5/26/2015)... DC (PRWEB) May 26, 2015 ... podiatrist Dr. Enzo J. Leone (Pasadena and ... service as the Maryland Podiatric Medical Association (MPMA) President ... , Dr. Leone received his Doctorate in Podiatric Medicine ... at the West Jersey Hospital in Voorhees, New Jersey. ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 U.S. Food ... in the United States are extensive and can be ... firm that helps medical device companies comply with FDA ... medical device companies navigate FDA requirements. , 1. ... the United States can be a lengthy process depending ...
Breaking Medicine News(10 mins):Health News:The Human Wellness Company Trivedi Master Wellness™ Opens a Complimentary Transformational Community Call to the Public on June 4, 2015 2Health News:The Human Wellness Company Trivedi Master Wellness™ Opens a Complimentary Transformational Community Call to the Public on June 4, 2015 3Health News:Vasont Systems Certifies the Integration between the Vasont® Component Content Management System and oXygen® XML Editor 17.0 2Health News:General Networks Corporation Announces Alliance with MarkLogic 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives MPMA Service Award 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 3Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 4
... ever-growing menace on the Internet. Now a millennium ... health related web-sites that are such havens of ... guideline for surfers to be weary of tall ... can be accessed on http://www.ratbags.com/rsoles/categories.htm, ,Statutary Warning: ...
... in Russia have reported to have said that more than ... every second newborn discharged from a maternity clinic is suffering ... from 45.3 percent in 1992 to just 30 percent last ... Russia's Academy of Medical Science. She thinks that the decline ...
... predict overall long-term survival rates in both men and women. ... , ,Researchers studied survival rates based on a lung ... performed the lung function test on a group of more ... in age from 20 to 89 years at enrollment. They ...
... Transdermal hormone replacement therapy (HRT) does not ... postmenopausal women with existing ,coronary artery disease ... ,Atherosclerosis Study), researchers randomized 255 ,postmenopausal women ... receive either transdermal HRT--17-beta-estradiol ,with or without ...
... in the membranes of red ,blood cells infected by ... Plasmodium falciparum, apparently uses these holes to supply itself ... , ,The discovery may lead to the development ... disease. ,Malaria kills more than one million people each ...
... ability to regulate ,their blood sugar by adding a little ... recognize and respond to insulin, the hormone that removes excess ... a test tube and in animal studies, the spice appeared ... is too soon to recommend the spice as a regular ...
Cached Medicine News:Health News:Feeding channel created by malaria parasite - a new target for ,malaria treatments 2
Only SurLok combines precise control, enhanced basket and grasper strength, and the added security of a unique wire-locking mechanism. You can feel the difference. The SurLok flat-wire and grasper ha...
The SurLok helical stone baskets are constructed of strong and resilient stainless steel. These helical baskets present a spiral profile that effectively clears both stones and fragments....
... The 3-way design permits ... irrigation lumen in the Foley ... in Latex construction, as well ... a wide variety of models ...
... facilitates negotiation of the prostatic urethra. ... length olive Coude tip with a ... construction provides added stiffness and radiopacity. ... a variety of materials, eye configurations, ...
Medicine Products: